Christie Arrasate
- Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK studyBy Marc Decramer, Jadwiga A. Wedzicha, Joachim H. Ficker, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiMarc Decramer1Respiratory Division, University Hospitals, Leuven, BelgiumJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomJoachim H. Ficker3Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK studyBy Joachim H. Ficker, Jadwiga A. Wedzicha, Marc Decramer, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiJoachim H. Ficker1Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomMarc Decramer3Respiratory Division, University Hospitals, Leuven, BelgiumAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK studyBy Joachim H. Ficker, Jadwiga A. Wedzicha, Marc Decramer, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiJoachim H. Ficker1Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomMarc Decramer3Respiratory Division, University Hospitals, Leuven, BelgiumAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK studyBy Marc Decramer, Jadwiga A. Wedzicha, Joachim H. Ficker, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiMarc Decramer1Respiratory Division, University Hospitals, Leuven, BelgiumJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomJoachim H. Ficker3Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK studyBy Jadwiga A. Wedzicha, Marc Decramer, Joachim H. Ficker, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiJadwiga A. Wedzicha1Centre for Respiratory Medicine, University College London, London, United KingdomMarc Decramer2Respiratory Division, University Hospitals, Leuven, BelgiumJoachim H. Ficker3Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.